Karen Autio, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Karen Autio, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07111507 · A Study of Tarlatamab for People With Prostate CancerMemorial Sloan Kettering Cancer Center · recruiting · Metastatic Prostate Cancer · principal investigator
- Ph1/Ph2NCT04019327 · A Study of the Drugs Talazoparib and Temozolomide in Prostate CancerMemorial Sloan Kettering Cancer Center · terminated · Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm · principal investigator
- Ph2NCT03810105 · A Study of Olaparib and Durvalumab in Prostate CancerMemorial Sloan Kettering Cancer Center · terminated · Prostate Cancer · principal investigator
- Ph2NCT02020070 · Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyMemorial Sloan Kettering Cancer Center · completed · Metastatic Castration Sensitive Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.